International Stem Cell Corp. (ISCO) Protecting it
Post# of 124
Posted On: 06/14/2016 4:34:45 PM
International Stem Cell Corp. (ISCO) Protecting its Technology Worldwide
A patent is essentially a government license that gives certain rights to the patent holder, excluding others from making, using, or selling a particular product or invention without permission. According to WIPO’s 2015 World Intellectual Property Indicators Report, there have been more than 2.7 million patent filings worldwide since 2013 and this number has grown significantly in recent years. The top three offices in the world have been in China, the U.S., and Japan. According to the report, the leading technology fields are computer technology, electrical machinery, measurement, and digital communication, with medical technology not far behind.
International Stem Cell Corporation (OTCQB: ISCO) is a publicly traded biotechnology company that promises to advance the field of regenerative medicine by addressing the problem of immune-rejection. Most recently, the company has focused its efforts on using unfertilized human eggs to create parthenogenetic stem cells to treat severe diseases of the eyes and nervous system, including diseases such as Parkinson’s. The company is careful to protect its associated intellectual property.
International Stem Cell Corporation protects its technology worldwide by filing and holding patent applications for its more specific stem cell lines, methods of production, and various research methods. So far, ISCO has 16 issued patents and 91 pending patents across 15 patent families, as well as a licensed portfolio of 25 patents or patents applications across eight patent families related to its skin care products. Most of International Stem Cell Corp.’s patents are filed internationally, covering the U.S., Canada, and a wide range of other industrialized countries.
The company’s technology strengths are backed up by a carefully chosen team of managers and scientists. ISCO’s directors, executive managers, and scientific advisors have been selected to benefit the company’s business and science related operations. Each person is skilled in particular aspects of corporate management or biotechnology, with executive managers specializing in systems analysis, strategic planning and corporate management, as well as financial management, accounting, medical genetics, embryology, and stem cell biology. This level of combined experience enables ISCO to function positively in every aspect of its business.
For more information, visit www.internationalstemcell.com
Please read full disclaimers at http://disclaimer.missionir.com
A patent is essentially a government license that gives certain rights to the patent holder, excluding others from making, using, or selling a particular product or invention without permission. According to WIPO’s 2015 World Intellectual Property Indicators Report, there have been more than 2.7 million patent filings worldwide since 2013 and this number has grown significantly in recent years. The top three offices in the world have been in China, the U.S., and Japan. According to the report, the leading technology fields are computer technology, electrical machinery, measurement, and digital communication, with medical technology not far behind.
International Stem Cell Corporation (OTCQB: ISCO) is a publicly traded biotechnology company that promises to advance the field of regenerative medicine by addressing the problem of immune-rejection. Most recently, the company has focused its efforts on using unfertilized human eggs to create parthenogenetic stem cells to treat severe diseases of the eyes and nervous system, including diseases such as Parkinson’s. The company is careful to protect its associated intellectual property.
International Stem Cell Corporation protects its technology worldwide by filing and holding patent applications for its more specific stem cell lines, methods of production, and various research methods. So far, ISCO has 16 issued patents and 91 pending patents across 15 patent families, as well as a licensed portfolio of 25 patents or patents applications across eight patent families related to its skin care products. Most of International Stem Cell Corp.’s patents are filed internationally, covering the U.S., Canada, and a wide range of other industrialized countries.
The company’s technology strengths are backed up by a carefully chosen team of managers and scientists. ISCO’s directors, executive managers, and scientific advisors have been selected to benefit the company’s business and science related operations. Each person is skilled in particular aspects of corporate management or biotechnology, with executive managers specializing in systems analysis, strategic planning and corporate management, as well as financial management, accounting, medical genetics, embryology, and stem cell biology. This level of combined experience enables ISCO to function positively in every aspect of its business.
For more information, visit www.internationalstemcell.com
Please read full disclaimers at http://disclaimer.missionir.com
(0)
(0)